An inadequate management of pain and different degrees of responsiveness to pain treatment represent significant problems for most surgical patients.
There is an urgent need to develop new analgesics which could have significant clinical, economic and societal benefits.
ANS Biotech, your partner for building your preclinical package step by step
Surgery aims either to repair a part of the body by reshaping or replacing it, or to remove dysfunctional elements. During surgical procedures, patients are artificially insensitive to pain, thanks to the use of gases or the injection of drugs.
It is estimated that up to 75% of patients undergoing various surgical procedures will experience pain related to their condition.
Postoperative pain (POP), is defined as a transient but extremely strong activation of the nociceptive network. For this reason, the anaesthetists give opioids at high doses during surgery. Furthermore, some procedures (such as incision of the skin and deeper tissues, dissection, electrocoagulation) induce lesions of tissues, which will need healing in the postoperative period.
The clinical aspects of sensitization are expressed as increased pain for a given stimulus. Such “hyperalgesia” may be detrimental in the early postoperative period, as it increases the amount of experienced POP may also induce stress. It is strongly linked to movement-evoked POP, against which the patient may behave by avoiding any painful movement. This strategy, of course may impact rehabilitation.
POP represents an estimated market size of $725 MM and remains a key indication with large patient potential.
How we can help you
Prior to moving into the clinic, preclinical investigations are necessary to evidence the efficacy of your compound in the postoperative pain area.
Within a preclinical pain project, four steps may be of value:
1- In terms of compound profiling, we can document the basics for your lead (dose range, side effects, plasma level, CNS exposure).
2- Using a screening approach, we can guide you in the selection of your candidate.
3- We can leverage a broad panel of disease models mimicking the pathophysiology mechanisms of postoperative pain to characterize the efficacy of your candidate.
4- We can mitigate the risk associated with clinical development by comparing your candidate versus standard of care agents.